| |
ICD-O-3
|
Males
|
Females
|
Male-to-female
|
|---|
|
Site
|
topography codes
|
No.
|
IR
|
No.
|
IR
|
IRR
|
(95 % CI)
|
|---|
|
Total§
|
00.0-80.9
|
28,820
|
96.20
|
26,902
|
71.44
|
1.35
|
(1.32, 1.37)†
|
|
SCLC
|
34.0-34.9
|
26,798
|
89.19
|
25,161
|
66.88
|
1.33
|
(1.31, 1.36)†
|
|
EPSCC
|
00.0-33.9, 35.0-75.9, 77.0-77.9
|
1,272
|
4.41
|
1,166
|
3.06
|
1.44
|
(1.33, 1.56)†
|
|
Salivary glands
|
07.9-08.9
|
44
|
0.16
|
<16
|
~
|
~
| |
|
Esophagus
|
15.0-15.9
|
106
|
0.36
|
81
|
0.21
|
1.72
|
(1.27, 2.33)†
|
|
Stomach
|
16.0-16.9
|
64
|
0.21
|
24
|
0.06
|
3.46
|
(2.12, 5.80)†
|
|
Colon/rectum
|
18.0-20.9
|
125
|
0.42
|
113
|
0.30
|
1.41
|
(1.08,1.84)†
|
|
Anus
|
21.0-21.8
|
16
|
0.05
|
21
|
0.06
|
0.95
|
(0.46, 1.91)
|
|
Liver/intrahepatic bile ducts
|
22.0-22.1
|
18
|
0.06
|
<16
|
~
|
~
| |
|
Gallbladder
|
23.9
|
<16
|
~
|
30
|
0.08
|
~
| |
|
Pancreas
|
25.0-25.9
|
89
|
0.30
|
84
|
0.22
|
1.38
|
(1.01, 1.88)†
|
|
Nose, nasal cavity, middle ear
|
30.0-30.1, 31.0-31.9
|
21
|
0.07
|
16
|
0.04
|
1.56
|
(0.77, 3.21)
|
|
Larynx
|
32.0-32.9
|
37
|
0.11
|
27
|
0.07
|
1.57
|
(0.93, 2.68)
|
|
Breast
|
50.0-50.9
|
<16
|
~
|
68
|
0.18
|
~
| |
|
Vagina
|
52.9
|
NA
|
NA
|
37
|
0.10
|
~
| |
|
Cervix
|
53.0-53.9
|
NA
|
NA
|
260
|
0.69
|
~
| |
|
Uterus
|
54.0-55.9
|
NA
|
NA
|
56
|
0.15
|
~
| |
|
Ovary
|
56.9
|
NA
|
NA
|
111
|
0.29
|
~
| |
|
Prostate
|
61.9
|
206
|
0.73
|
NA
|
NA
|
~
| |
|
Kidney and renal pelvis
|
64.9, 65.9
|
22
|
0.07
|
<16
|
~
|
~
| |
|
Urinary bladder
|
67.0-67.9
|
411
|
1.48
|
118
|
0.30
|
4.91
|
(3.99, 6.09)†
|
|
Unknown primary
|
76.0-76.8, 80.9
|
750
|
2.61
|
575
|
1.50
|
1.73
|
(1.55, 1.94)†
|
- Abbreviations: CI confidence interval, EPSCC extrapulmonary small cell carcinoma, ICD-O-3 third edition of the International Classification of Diseases for Oncology, NA not applicable, No. number of cases, SCLC small cell lung carcinoma, SEER-13 13 cancer registry areas of the Surveillance, Epidemiology and End Results Program, ~ IRs and IRRs are not calculated for <16 cases.
- *Incidence rates are age-adjusted to the 2000 U.S. standard population and expressed per 1,000,000 person-years. IRRs are based on unrounded rates.
- †95 % CI excludes 1.00 (based on unrounded upper and lower CI), and IRR is significant (P < 0.05).
- §Specified sites with 1–15 total cases not shown in the table (ICD-O-3 code): tongue (01.1-0.29), gum and other mouth (03.0-03.9, 05.0-05.9, 06.0-06.9), tonsil (09.0-09.9), oropharynx (10.0-10.9), hypopharynx (12.9, 13.0-13.9), other oral cavity and pharynx (14.0-14.8), small intestine (17.0-17.9), intestinal tract, unspecified (26.0-26.9), soft tissues, including heart (38.0, 47.0-47.9 49.0-49.9), retroperitoneum/peritoneum (48.0-48.8), vulva (51.0-51.9), other female genital (57.0-58.9), testis (62.0-62.9), other male genital (63.0-63.9), ureter (66.9), eye and orbit (69.0-69.9), thyroid (73.9), other endocrine (37.9, 74.0-74.9, 75.0-75.9), and lymph nodes (77.0-77.9). Sites with >15 cases, but with fewer than 16 among both, males and females, not specified in the table (No., IR, ICD-O-3 code): nasopharynx (No. = 23; IR = 0.03; 11.0-11.9), other biliary (No. = 19; IR = 0.03; 24.0-24.9), and trachea/mediastinum/other respiratory (No. = 25; IR = 0.04; 33.9, 38.1-39.9).
